{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:03:24Z","timestamp":1784217804161,"version":"3.55.0"},"update-to":[{"DOI":"10.12688\/f1000research.15512.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000}},{"DOI":"10.12688\/f1000research.15512.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000}}],"reference-count":31,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5U24OH009077-11"],"award-info":[{"award-number":["5U24OH009077-11"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000125","name":"National Institute for Occupational Safety and Health","doi-asserted-by":"publisher","award":["5U24OH009077-11"],"award-info":[{"award-number":["5U24OH009077-11"]}],"id":[{"id":"10.13039\/100000125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p><ns3:bold>Background<\/ns3:bold>: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US.\u00a0 Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. The overarching aim of this study is to examine survival of the cohort of patients with malignant mesothelioma enrolled in the National Mesothelioma Virtual Bank (NMVB). \u00a0<\/ns3:p><ns3:p> <ns3:bold>Methods: <\/ns3:bold>\u00a0888 cases of pleural and peritoneal mesothelioma cases were selected from the NMVB database, which houses data and associated biospecimens for over 1400 cases that were diagnosed from 1990 to 2017. Kaplan Meier\u2019s method was performed for survival analysis. The association between prognostic factors and survival was estimated using Cox Hazard Regression method and using R software for analysis.<\/ns3:p><ns3:p> <ns3:bold>Results: <\/ns3:bold>The median overall survival (OS) rate of all MM patients, including pleural and peritoneal mesothelioma cases is 15 months (14 months for pleural and 31 months for peritoneal). \u00a0Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were younger than 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and having combination treatment of surgical therapy with chemotherapy. Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies.<\/ns3:p><ns3:p> <ns3:bold>Conclusions:<\/ns3:bold> There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. Our findings show that combined surgical and chemotherapy treatment in peritoneal mesothelioma is associated with improved survival compared to local therapy alone.<\/ns3:p>","DOI":"10.12688\/f1000research.15512.3","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T09:55:07Z","timestamp":1559555707000},"page":"1184","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-7696","authenticated-orcid":false,"given":"Waqas","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-0104","authenticated-orcid":false,"given":"Faina","family":"Linkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P.","family":"Landsittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9252-6039","authenticated-orcid":false,"given":"Jonathan C.","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiam","family":"Bshara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Gaudioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-7990","authenticated-orcid":false,"given":"Jonathan","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Becich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"ref-1","first-page":"718-21","article-title":"Latent period for malignant mesothelioma of occupational origin.","volume":"34","author":"B Lanphear","year":"1992","journal-title":"J Occup Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"2736-40","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada.","volume":"46","author":"I Selikoff","year":"1980","journal-title":"Cancer."},{"key":"ref-3","article-title":"Case studies of existing human tissue repositories: \"Best Practice\" for a biospecimen resource for the genomic and proteomic era.","author":"E Eiseman","year":"2003"},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"147-57","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis.","volume":"9","author":"H Yang","year":"2008","journal-title":"Curr Treat Options Oncol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"576-88","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005.","volume":"39","author":"B Price","year":"2009","journal-title":"Crit Rev Toxicol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"82-8","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: Trend and features.","volume":"18","author":"C Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"843-50","DOI":"10.1136\/thoraxjnl-2013-204161","article-title":"Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis.","volume":"69","author":"A Reid","year":"2014","journal-title":"Thorax."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1996-2002","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.","volume":"35","author":"A Napolitano","year":"2016","journal-title":"Oncogene."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"565-576","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.","volume":"10","author":"M Nasu","year":"2015","journal-title":"J Thorac Oncol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"576-578","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard.","volume":"14","author":"F Baumann","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"731-737","DOI":"10.1097\/JTO.0000000000000506","article-title":"The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada.","volume":"10","author":"F Baumann","year":"2015","journal-title":"J Thorac Oncol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1246-1262","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma.","volume":"11","author":"M Carbone","year":"2016","journal-title":"J Thorac Oncol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"44-58","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses.","volume":"227","author":"M Carbone","year":"2012","journal-title":"J Cell Physiol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"79-86","DOI":"10.3978\/j.issn.2078-6891.2015.134","article-title":"Diagnosis and management of patients with malignant peritoneal mesothelioma.","volume":"7","author":"H Alexander","year":"2016","journal-title":"J Gastrointest Oncol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"985-90","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review.","volume":"18","author":"P Boffetta","year":"2007","journal-title":"Ann Oncol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"375-86","DOI":"10.1007\/s11864-002-0003-6","article-title":"Peritoneal mesothelioma.","volume":"3","author":"F Mohamed","year":"2002","journal-title":"Curr Treat Options Oncol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1587-93","DOI":"10.1046\/j.1365-2168.2000.01571.x","article-title":"Results of treatment of 33 patients with peritoneal mesothelioma.","volume":"87","author":"G Sebbag","year":"2000","journal-title":"Br J Surg."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/1471-2407-8-236","article-title":"National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research.","volume":"8","author":"W Amin","year":"2008","journal-title":"BMC Cancer."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"e0145039","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.","volume":"10","author":"E Taioli","year":"2015","journal-title":"PLoS One."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"23-32","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.","volume":"196","author":"R Meyerhoff","year":"2015","journal-title":"J Surg Res."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"731-5","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.","volume":"55","author":"J Edwards","year":"2000","journal-title":"Thorax."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1269-1283","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific Advances and New Frontiers in Mesothelioma Therapeutics.","volume":"13","author":"L Mutti","year":"2018","journal-title":"J Thorac Oncol."},{"key":"ref-23","doi-asserted-by":"crossref","first-page":"1645-58","DOI":"10.5858\/2010-0086-RAR.1","article-title":"Sarcomatoid neoplasms of the lung and pleura.","volume":"134","author":"W Travis","year":"2010","journal-title":"Arch Pathol Lab Med."},{"key":"ref-24","doi-asserted-by":"crossref","first-page":"1304-9","DOI":"10.1097\/00000478-200110000-00012","article-title":"Well-differentiated papillary mesothelioma.","volume":"25","author":"K Butnor","year":"2001","journal-title":"Am J Surg Pathol."},{"key":"ref-25","article-title":"R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria","year":"2013"},{"key":"ref-26","doi-asserted-by":"crossref","first-page":"605-21, xi","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington Cancer Institute.","volume":"12","author":"P Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"194-200","DOI":"10.1002\/ijc.23866","article-title":"Survival of peritoneal malignant mesothelioma in Italy: a population-based study.","volume":"124","author":"D Mirabelli","year":"2009","journal-title":"Int J Cancer."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"145-52","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.","volume":"16","author":"D Curran","year":"1998","journal-title":"J Clin Oncol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"957-65","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.","volume":"2","author":"R Flores","year":"2007","journal-title":"J Thorac Oncol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1860-9","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.","volume":"111","author":"A Linton","year":"2014","journal-title":"Br J Cancer."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.21037\/atm.2017.03.74","article-title":"Environmental asbestos exposure and risk of mesothelioma.","volume":"5","author":"C Noonan","year":"2017","journal-title":"Ann Transl Med."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:21:26Z","timestamp":1613992886000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":31,"URL":"https:\/\/doi.org\/10.12688\/f1000research.15512.3","relation":{},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.19194.r42130, Nico van Zandwijk, University of Sydney, Sydney, NSW, Australia, 15 Jan 2019, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v2#referee-response-42130","order":0,"name":"referee-response-42130","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.16914.r38743, Michele Carbone, Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, 10 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v1#referee-response-38743","order":1,"name":"referee-response-38743","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Waqas Amin<\/b>; \n<i>Posted: 13 Dec 2018<\/i>;  We have highlighted the importance mesotheliomas developing in carriers of germline mutations have significant improved survival. In the limitations, we recognize the fact that we do not have genetic information. We discuss the issue environmental exposure (Natural Occurring Asbestos) and occupational exposure and their association with pleural and peritoneal mesothelioma in introduction section. We recognize that we do not have radiological analysis to support exposure and rely on self-reported data. In our cohort of analysis, the ratio of pleural mesothelioma with asbestos exposure to malignant peritoneal mesothelioma with asbestos exposure is 23:277. Information on various exposures and BAP1 has been added to the introduction  We have updated the citations in the manuscripts and made minor corrections.","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3#referee-comment-4305","order":2,"name":"referee-comment-4305","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.16914.r39375, Tobias Peikert, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, 19 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v1#referee-response-39375","order":3,"name":"referee-response-39375","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Waqas Amin<\/b>; \n<i>Posted: 13 Dec 2018<\/i>;  We agree that our large cohort may not be representative of the general population of such patients and we recognize this weakness in the limitations section. NMVB cohort had very small number of cases that were not surgical candidates for their treatment of disease. We have not analyzed them because of insufficient number for meaningful statistical analysis. The specific treatment information has not collected in NMVB database. However, in future studies we will pull the information of specific treatments and include them in the analysis. Again, this limitation is recognized in the paper. We have highlight the issue related to younger age patients BAP1 mutation status in our introduction section paragraph 2. We would like to point out that we do not have such information in our database as of December 2018. There is a significant number of non-European American participants in the NMVB cohort due to geographic location of resource and its participants. We will further explore racial differences in survival in our future papers.  \n<b>Response to Minor Comments:<\/b>Corrected.","URL":"https:\/\/f1000research.com\/articles\/7-1184\/v3#referee-comment-4304","order":4,"name":"referee-comment-4304","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work is funded and supported by the Centers for Disease Control and Prevention (CDC) in association with the National Institute for Occupational Safety and Health (NIOSH) Grant [5U24OH009077-11]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":5,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}